Solvonis Therapeutics (LSE:SVNS) Total Stockholders Equity : £3.27 Mil (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Solvonis Therapeutics Total Stockholders Equity?

Solvonis Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2024 was £3.27 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Solvonis Therapeutics's Book Value per Share for the quarter that ended in Sep. 2024 was £0.00. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Solvonis Therapeutics's Debt-to-Equity for the quarter that ended in Sep. 2024 was 0.00.

Solvonis Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Solvonis Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solvonis Therapeutics Total Stockholders Equity Chart

Solvonis Therapeutics Annual Data

Trend

May18

May19

May20

May21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

1.70

1.25

4.55

2.03

3.08

Solvonis Therapeutics Quarterly Data
	May18	May19	May20	May21	Dec21	Jun22	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial								-	2.03	1.66	3.27	3.08

Solvonis Therapeutics (LSE:SVNS) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Solvonis Therapeutics's Book Value per Share for the quarter that ended in Sep. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(3.272	-	0)	/	2295.931
	=	0.00

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Solvonis Therapeutics's Debt-to-Equity for the quarter that ended in Sep. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	3.272
	=	0.00

Solvonis Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Solvonis Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Solvonis Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Solvonis Therapeutics PLC (LSE:SVNS) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Eccleston Yards, 25 Eccleston Place, London, GBR, SW1W 9NF

Website

https://www.solvonis.com

Solvonis Therapeutics PLC, formerly Graft Polymer (UK) PLC focuses on the development of polymer modification and drug delivery systems. It has licensed its Drug Delivery System platform IP to MGC Pharmaceuticals in relation to MGC Pharma's CimetrA product. The group's products address customer needs across a wide range of end-use markets, from automotive through to medical, and are not dependent on one market segment. The Company operates in two business segments being polymer development and production in Slovenia.

Solvonis Therapeutics Headlines

No Headlines